Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis
- 30 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 69 (12), 2665-2671
- https://doi.org/10.1007/s00262-020-02687-5
Abstract
Introduction A hypersensitivity response akin to immune reconstitution inflammatory syndrome (IRIS) has been proposed as a mechanism responsible for anti-PD-1 therapy-induced tuberculosis. IRIS is associated with enhanced activation of IL-17A-expressing CD4 + T cells (Th17). Gut microbiota is thought to be linked to pulmonary inflammation through the gut-lung axis. Materials and methods We used ImmuCellAI to investigate the T cell population in lung cancer and tuberculosis samples. Then, we applied flow cytometry to monitor the expression levels of the Th17 cell activation marker CD38 in the peripheral blood of a patient experiencing adverse events, including tuberculosis, in response to pembrolizumab. The gut microbiome was examined by 16S rRNA sequencing to examine the alterations caused by pembrolizumab. Results The percentage of Th17 cells was increased in both lung cancer and tuberculosis. FACS analysis showed that pembrolizumab induced substantial CD38 expression in Th17 cells. The patient's fecal samples showed that the diversity of the gut microbiota was significantly increased in response to the pembrolizumab cycle. One enriched genus wasPrevotella, which has previously been linked to lung inflammation and Th17 immune activation. Discussion The observed Th17 activation in our patient was consistent with a role of Th17-mediated IRIS in pembrolizumab-triggered tuberculosis. Pembrolizumab might trigger airway inflammation with a Th17 phenotype through microbiota interactions in the gut-lung axis.Funding Information
- Natural Science Foundation of China (81371777, 81873884)
- Natural Science Foundation of China (81770010)
This publication has 31 references indexed in Scilit:
- Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendationsJournal for ImmunoTherapy of Cancer, 2019
- Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer PatientsClinical Cancer Research, 2019
- Implications of Tuberculosis Reactivation after Immune Checkpoint InhibitionAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatmentClinical Microbiology & Infection, 2018
- Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non–Small Cell Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancerActa Oncologica, 2018
- Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade ImmunotherapyJournal of Thoracic Oncology, 2017
- Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti–PD-1 Treatment in a Patient with Advanced Pulmonary AdenocarcinomaJournal of Thoracic Oncology, 2017
- Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary TuberculosisJournal of Thoracic Oncology, 2016
- B Cells and Programmed Death-Ligand 2 Signaling Are Required for Maximal Interferon-γ Recall Response by Splenic CD4+ Memory T Cells of Mice Vaccinated with Mycobacterium tuberculosis Ag85BPLOS ONE, 2015